Copperwynd Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-10,248
Closed -$712K 163
2025
Q1
$712K Buy
10,248
+2,180
+27% +$180K 0.2% 104
2024
Q4
$694K Buy
8,068
+650
+9% +$70.3K 0.19% 90
2024
Q3
$883K Buy
7,418
+711
+11% +$94.8K 0.27% 74
2024
Q2
$890K Buy
6,707
+998
+17% +$132K 0.29% 57
2024
Q1
$733K Buy
5,709
+763
+15% +$90.8K 0.26% 74
2023
Q4
$512K Buy
+4,946
New +$489K 0.2% 98

Other funds holding NVO

Copperwynd Financial's NVO Position: Q2 2025 in Review

Copperwynd Financial sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 10,248 shares — an estimated $712K sold.

Copperwynd Financial first reported a position in NVO in Q4 2023 and held it in 6 quarters. The position peaked at $890K in Q2 2024. 1,482 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Copperwynd Financial reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Copperwynd Financial sold 10,248 Novo Nordisk shares in Q2 2025, an estimated $712K.
  • Copperwynd Financial first reported a position in Novo Nordisk in Q4 2023 and held it in 6 quarters.
  • Copperwynd Financial's Novo Nordisk position peaked at $890K in Q2 2024.
  • 1,482 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Copperwynd Financial's 13F filing for Q2 2025, filed 24 Jul 2025.